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Ticagrelor Versus Clopidogrel in Patients With Acute Coronary
Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis
From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Pontus Andell, MD; Stefan K. James, MD, PhD; Christopher P. Cannon, MD; Derek D. Cyr, PhD; Anders Himmelmann, MD, PhD;
Steen Husted, MD, DSc; Matyas Keltai, MD, PhD; Sasha Koul, MD; Anwar Santoso, MD, PhD; Ph. Gabriel Steg, MD;
Robert F. Storey, MD, DM; Lars Wallentin, MD, PhD; David Erlinge, MD, PhD; on behalf of the PLATO Investigators
Background-—Patients with chronic obstructive pulmonary disease (COPD) experiencing acute coronary syndromes (ACS) are at
high risk for clinical events. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the
primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea,
which may lead clinicians to withhold ticagrelor from COPD patients.
Methods and Results-—In 18 624 patients with ACS randomized to treatment with ticagrelor or clopidogrel, history of COPD was
recorded in 1085 (5.8%). At 1 year, the primary endpoint occurred in 17.7% of patients with COPD versus 10.4% in those without
COPD (P<0.001). The 1-year event rate for the primary endpoint in COPD patients treated with ticagrelor versus clopidogrel was
14.8% versus 20.6% (hazard ratio [HR]=0.72; 95% conﬁdence interval [CI]: 0.54 to 0.97), for death from any cause 8.4% versus
12.4% (HR=0.70; 95% CI: 0.47 to 1.04), and for PLATO-deﬁned major bleeding rates at 1 year 14.6% versus 16.6% (HR=0.85; 95%
CI: 0.61 to 1.17). Dyspnea occurred more frequently with ticagrelor (26.1% vs. 16.3%; HR=1.71; 95% CI: 1.28 to 2.30). There was
no differential increase in the relative risk of dyspnea compared to non-COPD patients (HR=1.85). No COPD status-by-treatment
interactions were found, showing consistency with the main trial results.
Conclusions-—In this post-hoc analysis, COPD patients experienced high rates of ischemic events. Ticagrelor versus clopidogrel
reduced and substantially decreased the absolute risk of ischemic events (5.8%) in COPD patients, without increasing overall major
bleeding events. The beneﬁt-risk proﬁle supports the use of ticagrelor in patients with ACS and concomitant COPD.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00391872. ( J Am Heart Assoc. 2015;4:
e002490 doi: 10.1161/JAHA.115.002490)
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P
atients with chronic obstructive pulmonary disease
(COPD) are at high risk of experiencing acute coronary
syndromes (ACS).
1
This high risk is partly attributed to
shared common risk factors, such as higher age, smoking,
2
and systemic inﬂammation.
3
In addition, reduced pulmonary
function, independent of smoking, has been associated with
increased risk of ACS, arrhythmias, and cardiovascular
death.
4–7
Patients with COPD experiencing ACS have
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subsequent increased risk of recurrent ischemic events and
increased all-cause mortality compared to those without
COPD.
8–11
This is, to a certain extent, explained by
comorbidities,
11
but it has been shown that patients with
COPD are less likely to receive reperfusion therapy and
guideline-recommended secondary prevention therapies,
which could further worsen long-term outcomes.
8,9,11,12
The PLATO study showed superior efﬁcacy of the non-
thienopyridine platelet P2Y12–receptor inhibitor, ticagrelor, as
compared to clopidogrel in preventing death from vascular
causes, myocardial infarction (MI), or stroke in patients with
ACS, without an increase in overall major bleeding events.
13
However, patients randomized to ticagrelor had increased
incidence of dyspnea, a known adverse effect commonly
characterized as mild to moderate and often transient without
being associated with either differences in efﬁcacy or safety
outcomes
14
or an adverse effect on pulmonary function.
15
Previous substudies from PLATO have shown ticagrelor to be
superior to clopidogrel in different high-risk patient popula-
tions, including patients with diabetes
16
or impaired renal
function,
17
and in the elderly.
18
Despite ACS patients with concomitant COPD being at
higher risk thus warranting efﬁcacious therapies, clinicians
may be reluctant to prescribe ticagrelor to these patients
owing to the increased incidence of dyspnea. At the time the
PLATO trial was published, an accompanying editorial dis-
couraged the use of ticagrelor in patients with COPD.
19
Furthermore, the European Medicines Agency assessment
report indicates caution when prescribing ticagrelor to
patients with history of COPD, owing to a potentially
increased absolute risk of dyspnea.
20
Thus, the aim of the
present study was to study the efﬁcacy and safety proﬁle of
ticagrelor versus clopidogrel in ACS patients with COPD.
Methods
The PLATO trial (http://www.clinicaltrials.gov identiﬁer:
NCT00391872) enrolled 18 624 patients between October
2006 and July 2008. Details about the study design, patients,
outcome deﬁnitions, and results have been published.
13,21
In
each country, the study was approved by national regulatory
authorities and by local ethics committees or institutional
review boards, according to local regulations. All patients
provided written consent to participate in the study. Patients
were eligible for enrollment if they were hospitalized for ACS,
with or without ST-segment elevation, and with symptom
onset during the previous 24 hours. Major exclusion criteria
were contraindication to clopidogrel, ﬁbrinolytic therapy
within 24 hours before randomization, a need for oral
anticoagulation therapy, an increased risk of bradycardia,
and simultaneous therapy with a strong cytochrome P450 3A
inhibitor or inducer. Patients were randomized to ticagrelor or
clopidogrel in a double-blind, double-dummy fashion. All
patients received acetylsalicylic acid unless intolerant. The
median treatment duration was 9.1 months.
The primary efﬁcacy endpoint was time to ﬁrst occurrence
of any event from the composite endpoint consisting of death
from vascular causes, MI, or stroke. Secondary efﬁcacy
endpoints were individual events of MI, stroke, death from
vascular causes, and death from any cause. The primary
safety endpoint was time to ﬁrst occurrence of major
bleeding, deﬁned by the study criteria. In addition, bleeding
events deﬁned according to the TIMI criteria, and life-
threatening or fatal bleeding (deﬁned by the study criteria)
were also assessed. Other adverse events, including dyspnea,
were recorded in the electronic case report form. Each on-site
investigator assessed COPD status at the time of randomiza-
tion and reported in the case report form whether the patient
had “current COPD” or “no COPD.”
Statistical Analyses
Baseline patient characteristics were compared by COPD
status. Continuous variables are presented as medians (25th
to 75th percentile) and differences were compared using the
Wilcoxon rank-sum test. Categorical variables are presented
as counts (percentages) and differences were compared using
the Pearson chi-square test when the cell frequencies were
sufﬁcient; otherwise, an exact test was used. For patients with
and without COPD, Kaplan–Meier event rates 12 months after
randomization were calculated separately for ticagrelor- and
clopidogrel-treated groups, for each efﬁcacy and safety
endpoint. Cox proportional hazards regression was used to
characterize the randomized treatment effect in patients with
and without COPD. For each endpoint, the hazard ratio (HR;
95% conﬁdence interval [CI]) for the COPD cohort and non-
COPD cohort and treatment-by-COPD interaction P value are
reported. Cox proportional hazard regression was also used to
characterize the univariate, age-adjusted, and multivariate
HRs with 95% CI for the primary efﬁcacy endpoint in patients
with COPD versus patients without COPD. Adjustment
covariates include: previous MI, previous nonhemorrhagic
stroke, heart rate, Killip class at entry, age, white blood cells,
peripheral artery disease, previous coronary artery bypass
grafting (CABG), time from symptoms to randomization,
diabetes, hemoglobin, region, changes in electrocardiogram
at entry, ﬁnal diagnosis of index event, previous transient
ischemic attack, randomized treatment, and creatinine.
Continuous variables were assessed for linearity on the log-
hazard scale, and, when appropriate, linear splines were used
to account for nonlinear relationships with the primary
efﬁcacy endpoint.
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Table 1. Baseline Characteristic According to COPD Status
Characteristic
COPD
(N=1085)
No COPD
(N=17 528) P Value
Demographics
Age, yr 67 (59 to 73) 62 (54 to 70) <0.001
Age ≥75 years 236/1085 (21.8) 2640/17 528 (15.1) <0.001
Female gender 325/1085 (30.0) 4959/17 528 (28.3) 0.239
Race 0.002
Caucasian 1010/1085 (93.1) 16 057/17 528 (91.6)
Black 19/1085 (1.8) 210/17 528 (1.2)
Oriental 39/1085 (3.6) 1057/17 528 (6.0)
Other 17/1085 (1.6) 204/17 528 (1.2)
BMI, kg/m2 27.7 (24.2 to 31.1) 27.4 (24.7 to 30.4) 0.644
Waist circumference, cm 100 (90 to 110) 98 (90 to 106) <0.001
Smoking status <0.001
Nonsmoker 204/1085 (18.8) 7052/17 525 (40.2)
Ex-smoker 390/1085 (35.9) 4286/17 525 (24.5)
Habitual smoker 491/1085 (45.3) 6187/17 525 (35.3)
Medical history
Hypertension 783/1085 (72.2) 11 400/17 528 (65.0) <0.001
Dyslipidemia 585/1085 (53.9) 8104/17 527 (46.2) <0.001
Diabetes mellitus 292/1085 (26.9) 4370/17 528 (24.9) 0.144
Angina pectoris 632/1085 (58.2) 7726/17 528 (44.1) <0.001
Myocardial infarction 322/1085 (29.7) 3502/17 528 (20.0) <0.001
Congestive heart failure 152/1085 (14.0) 898/17 528 (5.1) <0.001
Coronary artery disease 441/1085 (40.6) 4685/17 528 (26.7) <0.001
PCI 225/1085 (20.7) 2267/17 527 (12.9) <0.001
CABG 132/1085 (12.2) 974/17 528 (5.6) <0.001
Transient ischemic attack 46/1085 (4.2) 453/17 528 (2.6) 0.001
Nonhemorrhagic stroke 47/1084 (4.3) 675/17 528 (3.9) 0.422
Peripheral artery disease 153/1085 (14.1) 991/17 528 (5.7) <0.001
Pacemaker 23/1085 (2.1) 133/17 528 (0.8) <0.001
Peptic ulcer disease 122/1085 (11.2) 1151/17 528 (6.6) <0.001
Gastrointestinal bleeding 44/1085 (4.1) 221/17 528 (1.3) <0.001
Asthma 118/1085 (10.9) 414/17 528 (2.4) <0.001
Chronic renal disease 93/1085 (8.6) 692/17 528 (3.9) <0.001
Biochemistry
Creatinine clearance [CG], mL/min 73.3 (56.4 to 91.9) 80.7 (63.4 to 99.3) <0.001
Glucose, mmol/L 6.7 (5.6 to 8.5) 6.9 (5.7 to 8.8) 0.023
HbA1c, % 6.1 (5.7 to 6.7) 6.0 (5.6 to 6.6) 0.020
Hemoglobin, g/L 138 (126 to 148) 140 (129 to 149) 0.002
Total cholesterol, mmol/L 4.8 (4.1 to 5.8) 5.1 (4.4 to 6.0) <0.001
LDL cholesterol, mmol/L 2.9 (2.2 to 3.6) 3.1 (2.4 to 3.9) <0.001
HDL cholesterol, mmol/L 1.2 (1.0 to 1.5) 1.2 (1.0 to 1.4) 0.377
First central TnI positive 883/1085 (81.4) 14 205/17 528 (81.0) 0.889
Continued
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All analyses were performed according to the intention-to-
treat deﬁnition with SAS software (version 9.2; SAS Institute
Inc., Cary, NC). A 2-sided P value of 0.05 was considered
statistically signiﬁcant for overall treatment differences.
Results
Patient Characteristics
Of 18 624 patients randomized in the PLATO study, 1085
(5.8%) were reported by the investigators as having COPD.
These patients were older and more often current or ex-
smokers (Table 1). They more frequently had multiple cardio-
vascular risk factors and comorbidities, including a history of
angina pectoris, MI, congestive heart failure, and coronary
artery disease. In addition, COPD patients had lower median
creatinine clearance, were less often treated with beta-
blockers, and more often treated with diuretics. In regard to
treatment approach, patients with COPD were less frequently
invasively investigated. Furthermore, fewer COPD patients
were diagnosed with ST-segment elevation myocardial infarc-
tion (STEMI).
Baseline characteristics, medications, and treatment
approach were well matched between the randomized
treatment groups (Table S1).
Ischemic and Bleeding Outcomes in Relation to
COPD Status and Randomized Treatment
Rates of both ischemic and bleeding events were higher in
patients with COPD compared to those without COPD
(Figure 1), and crude all-cause mortality was doubled (10.4%
vs. 4.9%; HR=2.09; 95% CI: 1.70 to 2.57). The univariate, age-
adjusted, and multivariate HRs for the primary composite
endpoint for COPD patients versus non-COPD patients were
1.75 (95% CI: 1.50 to 2.04), 1.53 (95% CI: 1.31 to 1.79), and
1.31 (95% CI: 1.09 to 1.57), respectively.
Ticagrelor signiﬁcantly reduced the primary composite
endpoint of death from vascular causes, MI, or stroke, both in
patients with or without COPD (Figures 1 and 2). The relative
reduction in the rate of the primary endpoint with ticagrelor
was similar between COPD and non-COPD patients and
consistent with the main trial ﬁndings, but the absolute
reduction was greater in patients with COPD (5.8% vs. 1.5%).
Table 1. Continued
Characteristic
COPD
(N=1085)
No COPD
(N=17 528) P Value
Medications at randomization
Aspirin 997/1085 (91.9) 16 428/17 511 (93.8) 0.011
Unfractionated heparin 536/1085 (49.4) 8922/17 511 (51.0) 0.322
Low molecular weight heparin 460/1085 (42.4) 6855/17 511 (39.1) 0.033
GP IIb/IIIa inhibitors 234/1085 (21.6) 4345/17 511 (24.8) 0.016
Beta blockers 673/1085 (62.0) 12 324/17 511 (70.4) <0.001
ACE inhibitors 628/1085 (57.9) 9893/17 511 (56.5) 0.372
Angiotensin II receptor blockers 126/1085 (11.6) 1519/17 511 (8.7) <0.001
Statins 839/1085 (77.3) 13 864/17 511 (79.2) 0.147
Calcium channel blockers 181/1085 (16.7) 2527/17 511 (14.4) 0.041
Diuretics 416/1085 (38.3) 3906/17 511 (22.3) <0.001
Proton pump inhibitors 427/1085 (39.4) 5946/17 511 (34.0) <0.001
Nitrates 794/1085 (73.2) 12 235/17 511 (69.9) 0.021
Intended treatment approach 0.004
Invasive 740/1085 (68.2) 12 658/17 528 (72.2)
Medically managed 345/1085 (31.8) 4870/17 528 (27.8)
Final diagnosis <0.001
NSTEMI/UA 736/1085 (67.8) 10 333/17 528 (59.0)
STEMI 349/1085 (32.2) 7195/17 528 (41.0)
ACE indicates angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; GP IIb/IIIa, glycoprotein IIb/IIIa;
HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-
elevation myocardial infarction; TnI, troponin I; UA, unstable angina.
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No COPD status-by-treatment interactions were found in the
efﬁcacy endpoint analyses. In line with the main trial,
ticagrelor was associated with a reduction in death from
any cause in patients with or without COPD (interaction
P=0.557).
For COPD and non-COPD patients, no signiﬁcant difference
in the rates of overall major bleeding, regardless of using
PLATO (Figure 3) or thrombolysis in myocardial infarction
study group (TIMI) criteria, was observed between ticagrelor-
and clopidogrel-treated patients (Figure 1). In accord with the
main trial, ticagrelor was associated with increased PLATO-
deﬁned non-CABG-related major bleeding in non-COPD
patients, but in COPD patients these rates were similar,
although the interaction analysis was not signiﬁcant
(P=0.059). No interaction tests were signiﬁcant irrespective
of bleeding type and deﬁnition.
Dyspnea-Related Outcomes, Discontinuation of
Study Drug, and Adverse Events
Ticagrelor signiﬁcantly increased the incidence of dyspnea,
both in patients with and without COPD (Figure 1). Although
absolute dyspnea event rates were higher in COPD patients,
ticagrelor-associated relative risks were similar and no COPD
status-by-treatment interaction was found (P=0.616). Dysp-
nea-related discontinuation of study drug was more common
with ticagrelor, irrespective of COPD status. COPD patients
treated with ticagrelor showed numerically more dyspnea-
related events leading to discontinuation of study drug
compared to non-COPD patients (2.5% vs. 0.9%), although
the numbers of discontinuations were very small. Overall
premature discontinuation of study drug was more common in
COPD patients treated with ticagrelor (Table 2).
Figure 1. The percentages are Kaplan–Meier (K-M) estimates of the rate of the endpoint at 12 months. CABG indicates coronary artery
bypass graft; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; TIMI, thrombolysis in myocardial
infarction study group.
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Adherence to study drug, deﬁned as the use of more than
80% of the study medication during each interval between
visits, was slightly higher in COPD patients treated with
ticagrelor, whereas the exposure, meaning total days on
treatment, was slightly lower. There were more adverse
events (AEs) related to dyspnea in patients with COPD treated
with ticagrelor (Table 2). The numbers of serious AEs (SAEs)
were small. The suspected etiologies of dyspnea events are
shown in Table S2.
Subgroup Analyses
Efﬁcacy and safety outcomes in subgroups deﬁned by initial
treatment approach (invasive investigation vs. medically man-
aged) were consistent with the main ﬁndings (data not shown).
Likewise, an additional analysis with nonsmokers excluded was
also consistent with the main ﬁndings (data not shown).
Discussion
In line with other published studies,
8–11
the PLATO trial
highlights patients with COPD as a high-risk population when
experiencing ACS, shown by both increased risk of recurrent
ischemic and bleeding events as well as by doubled crude
Figure 2. Cumulative Kaplan–Meier estimates of the time to
ﬁrst adjudicated occurrence of the primary efﬁcacy endpoint (a
composite of death from vascular causes, myocardial infarction,
or stroke). Chronic obstructive pulmonary disease (COPD)
patients randomized to ticagrelor or clopidogrel are represented
by solid blue and red lines, respectively, and non-COPD patients
randomized to ticagrelor or clopidogrel are represented by dashed
blue and red lines, respectively. K-M indicates Kaplan–Meier.
Figure 3. Cumulative Kaplan–Meier estimates of the time to
ﬁrst PLATO-deﬁned major bleeding event. COPD patients ran-
domized to ticagrelor or clopidogrel are represented by solid blue
and red lines, respectively, and non-COPD patients randomized to
ticagrelor or clopidogrel are represented by dashed blue and red
lines, respectively. COPD indicates chronic obstructive pulmonary
disease; K-M, Kaplan–Meier; PLATO, Platelet Inhibition and
Patient Outcomes.
Table 2. Randomized Treatment Use and Dyspnea-Related
AEs
No. of COPD Patients, No. (%)
Ticagrelor
(n=555)
Clopidogrel
(n=530)
Discontinuation and adherence
Premature discontinuation of
study drug
184 (33.2) 140 (26.4)
Adherence* to study drug 436 (78.6) 395 (74.5)
Exposure to study drug,
median (IQR)
266 (65 to 364) 278 (99 to
364)
AE summary
Dyspnea as the predominant
symptom
111 (20.0) 64 (12.1)
SAE 10 (1.8) 5 (0.9)
AE is serious owing to†—No./SAE (%)
Death 0/10 (0.0) 0/5 (0.0)
Life threatening 3/10 (30.0) 0/5 (0.0)
In-patient hospitalization or
prolongation
of hospitalization
10/10 (100.0) 5/5 (100.0)
Persistent or significant disability/
incapacity
2/10 (20.0) 1/5 (20.0)
A congenital abnormality/birth
defect
0/10 (0.0) 0/5 (0.0)
Important medical event 5/10 (50.0) 1/5 (20.0)
AE indicates adverse event; COPD chronic obstructive pulmonary disease; IQR,
interquartile range; SAE, serious AE.
*Adherence to the study drug was deﬁned as the use of more than 80% of the study
medication during each interval between visits, as assessed by the site investigator.
†
According to the SAE Report form, a patient can have multiple criteria selected for
classifying the AE as serious.
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all-cause mortality after an ACS. In the present study, patients
with COPD were older with a particularly high-risk proﬁle,
including higher prevalence of congestive heart failure, coro-
nary artery disease, and chronic renal disease ﬁndings similar to
previous observational data.
11,22
In regard to treatment
approach, COPD patients were slightly less often planned for
invasive investigation, but guideline-recommended therapies
were still prescribed to a high extent (except beta-blockers), a
ﬁnding in contrast with the general undertreatment observed in
many observational studies.
8,11,12,23
The most important ﬁnding in the present study is that
ticagrelor, compared to clopidogrel, signiﬁcantly reduced the
primary efﬁcacy endpoint consisting of death from vascular
causes, MI, and stroke regardless of COPD status, without
increasing the rate of overall major bleeding. In the COPD
subset, the absolute risk reduction by ticagrelor versus
clopidogrel was 4 times greater, as compared to those without
COPD. The ﬁndings in this study and other high-risk subgroup
analyses from PLATO suggest that patients at greater risk have
increased absolute beneﬁt of ticagrelor.
16,17,24
In terms of bleeding, the results from the present study
align with the main trial results, with similar overall major
bleeding rates between ticagrelor- and clopidogrel-treated
groups. In the main trial, PLATO-deﬁned non-CABG-related
major bleeding was increased in patients treated with
ticagrelor. However, in the present study, this increase was
found in the non-COPD-cohort, but not in the COPD cohort,
though the interaction analysis did not reach statistical
signiﬁcance (P=0.059).
Although there was no relative increase in ticagrelor-
related dyspnea in the COPD cohort, there was a higher
absolute risk of dyspnea in these patients. Even though more
than 1 quarter of the ticagrelor-treated COPD patients
experienced dyspnea, only 2.5% of these patients discontin-
ued ticagrelor because of dyspnea, compared to 0.9% among
ticagrelor-treated patients without COPD. Furthermore, the
number of SAEss related to dyspnea was few and none were
fatal. Most important, the overall ischemic event rate was
much lower in the ticagrelor-treated COPD subset, despite the
high incidence of dyspnea, in accord with previous studies of
ticagrelor-related dyspnea showing that it is often transient
and usually mild to moderate in severity without any adverse
effect on either lung or heart function.
14,15,25
Limitations
This study was a post-hoc analysis not prespeciﬁed in the
original trial design. The COPD cohort of 1085 patients was not
powered to show a difference in the primary outcome between
the randomized groups. The randomization in PLATO was not
stratiﬁed for COPD status; therefore, some imbalance between
the groups may exist among the subset of patients with COPD.
Still, the COPD groups stratiﬁed by treatment were well
balanced regarding baseline characteristics. Furthermore,
because COPD status was assessed by the investigators and
not based on pulmonary function tests, the COPD cohort may
represent a more clinically evident and severe COPD pheno-
type. However, the assessments performed by the PLATO
investigators probably reﬂect the routine clinical setting.
Conclusions
Patients with ACS and concomitant COPD are a high-risk
population with a worse ischemic outcome as well as
increased bleeding rates. Ticagrelor signiﬁcantly reduced the
risk of ischemic events with an absolute reduction in COPD
patients that was nearly 4 times as great as in non-COPD
patients, without an increase in overall major bleeding. There
was no differential increase in the relative risk of dyspnea
compared to non-COPD patients, but the increase in absolute
risk was greater in COPD patients. Although a post-hoc
analysis, the beneﬁt-risk proﬁle supports the use of ticagrelor
in patients with ACS and COPD. In consideration of the
accumulated evidence that patients with COPD constitute a
high-risk population with a poor prognosis, who may also be
undertreated with guideline-recommended secondary preven-
tion, ticagrelor presents an opportunity to improve outcomes
in patients with ACS and COPD.
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